This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
This article highlights some recent million-dollar molecules, including: Gilead's exclusively licensed preclinical, oral IRAK4 degrader from Nurix Biohaven's exclusively licensed…
Article
5 months ago ●
6 mins read
This article discusses scientifically interesting molecules that have unfortunately had negative recent readouts. Aptinyx’s therapeutic approach of targeting positive allosteric…
Article
5 months ago ●
3 mins read
The AACR 2023 first disclosures presented in the Chemistry in Cancer Research’s “New Drugs on the Horizon” sessions are always…
Article
5 months ago ●
22 mins read
Merck’s oral PCSK9 inhibitor is a surprisingly bioavailable and orally effective macrocyclic peptide with picomolar activity. It recently demonstrated significant…
Article
5 months ago ●
11 mins read
Pfizer spinout, SpringWorks Therapeutics, was granted priority review by the FDA for its oral gamma secretase inhibitor for the treatment…
Article
5 months ago ●
5 mins read
A Ph. IIb TYK2 inhibitor from Nimbus (just bought by Takeda) that may be more efficacious than deucravacitinib, the first…
Article
6 months ago ●
2 mins read
Load More
